| 0.95 0 (0%) | 08-19 12:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.16 | 1-year : | 1.36 |
| Resists | First : | 1 | Second : | 1.16 |
| Pivot price | 0.95  |
|||
| Supports | First : | 0.91 |
Second : | 0.86 |
| MAs | MA(5) : | 0.95 |
MA(20) : | 0.94 |
| MA(100) : | 0.9 |
MA(250) : | 1.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58 |
D(3) : | 63.7 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 1.71 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INCR ] has closed above bottom band by 27.8%. Bollinger Bands are 65.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.98 - 0.98 | 0.98 - 0.99 |
| Low: | 0.94 - 0.94 | 0.94 - 0.95 |
| Close: | 0.94 - 0.95 | 0.95 - 0.96 |
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.
Wed, 19 Aug 2026
InterCure Ltd. Announces 1-for-5 Reverse Share Split - The Manila Times
Fri, 14 Aug 2026
InterCure Ltd (INCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tue, 11 Aug 2026
InterCure Ltd. (INCR) shareholders back proposal at August 11, 2026 special meeting - Stock Titan
Wed, 05 Aug 2026
Intercure (INCR) Slips 1.16% to $0.95, Hovering Above Key Support - High Conviction Picks - Vinanet
Wed, 22 Jul 2026
What Is Driving InterCure (NASDAQ:INCR) on the Nasdaq? - Kalkine Media
Mon, 22 Jun 2026
InterCure Secures NIS 22 Million Private Placement With Potential to Rise to NIS 54 Million for Global Expansion - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 59 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 39.1 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 47 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.59 |
| Profit Margin | -13.3 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -9.3 % |
| Qtrly Rev. Growth | 23.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -4.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.12 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|